The Weekly Five | 19–25 October

Five studies worth your time this week, spanning randomized breast radiotherapy, lung reirradiation, late brain toxicity, treatment sequencing and cardiac risk.

1. HypoMast-IMNI confirms noninferiority of 16-fraction postmastectomy RT

In high-risk breast cancer, 16-fraction RT including internal mammary nodes achieved noninferior five-year locoregional control (1.7% vs 2.2%) and reduced grade 3 acute skin toxicity from 12.2% to 1.7%.

Read post

2. ESTRO–ReCOG defines practical priorities for lung reirradiation

New consensus guidance emphasizes validated cumulative organ-at-risk dose assessment, individualized planning and daily volumetric imaging, while cautioning against unvalidated tissue-recovery assumptions.

Read post

3. Proton therapy shows no reduction in brain necrosis after nasopharyngeal RT

Brain necrosis occurred in 6.3% after proton RT versus 5.1% after photon IMRT, without a significant difference. Unequal follow-up and only 14 events limit interpretation.

Read post

4. Concurrent CDK4/6 inhibitors show similar discontinuation rates during breast RT

In 87 matched pairs, permanent CDK4/6 inhibitor discontinuation was 10.3% with concurrent RT versus 9.2% with sequential treatment. Rare severe toxicity remains a concern.

Read post

5. Rising heart rate during lung chemoradiotherapy signals subsequent arrhythmia risk

In 110 patients, resting heart rate rose from approximately 80 to 93 bpm during treatment. Higher sinoatrial node dose was associated with greater increases, while treatment-related tachycardia tracked with later arrhythmias.

Read post

That's the week. See you next Sunday.

Browse more research Suggest a correction